Summary & Overview
HCPCS S3865: Comprehensive Gene Sequence Analysis for Hypertrophic Cardiomyopathy
HCPCS Level II code S3865 represents comprehensive gene sequence analysis for hypertrophic cardiomyopathy, a specialized molecular diagnostic service used to detect genetic variants that contribute to inherited cardiac hypertrophy. This code is nationally relevant as precision genomic testing increasingly informs diagnosis, family screening, and management of cardiomyopathy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for hypertrophic cardiomyopathy testing, common payer coverage considerations, and benchmarking elements useful for laboratory and billing teams. The publication outlines expected sites of service, typical utilization scenarios, and what stakeholders should consider when documenting medical necessity for complex gene sequencing.
The report highlights: clinical purpose and operational use of S3865; payer coverage landscape and common contractual considerations; billing and coding nuances relevant to laboratories and cardiology clinics; and where to find additional policy resources. Data not available in the input is explicitly noted where applicable. This summary serves clinicians, lab directors, and revenue cycle professionals seeking a concise reference on the role and administrative handling of comprehensive genetic sequencing for hypertrophic cardiomyopathy under HCPCS Level II code S3865.
Billing Code Overview
HCPCS Level II code S3865 describes comprehensive gene sequence analysis for hypertrophic cardiomyopathy. The service involves broad genomic sequencing and interpretation aimed at identifying pathogenic or likely pathogenic variants associated with hypertrophic cardiomyopathy.
Service type: Genetic testing / molecular diagnostic testing for inherited cardiomyopathy.
Typical site of service: Clinical laboratories, outpatient genetic testing centers, or specialized cardiogenetics clinics where blood or other patient specimens are collected and sent for sequencing and interpretation.
Clinical & Coding Specifications
Clinical Context
A 34-year-old individual with exertional dyspnea, a systolic murmur, and a family history of sudden cardiac death is referred to a cardiomyopathy clinic for evaluation of suspected hypertrophic cardiomyopathy (HCM). After echocardiography demonstrates asymmetric septal hypertrophy and a cardiologist documents concern for an inherited cardiomyopathy, the clinician orders comprehensive gene sequence analysis for hypertrophic cardiomyopathy billed as S3865. Blood is collected in an appropriate specimen tube, sent to a certified molecular diagnostics laboratory, and DNA is extracted for next-generation sequencing of a cardiomyopathy gene panel. The laboratory performs sequence analysis, variant calling, and interpretation using current American College of Medical Genetics and Genomics (ACMG) standards, and issues a report classifying variants (pathogenic, likely pathogenic, VUS, likely benign, benign). Results are returned to the ordering cardiologist and integrated into clinical management, family cascade testing planning, and genetic counseling. Typical site of service is an outpatient specialty clinic or a molecular diagnostics laboratory; specimen collection occurs in an outpatient clinic, hospital outpatient phlebotomy, or ambulatory lab collection site. Common clinical workflow steps: pre-test counseling and consent, specimen collection, laboratory sequencing and bioinformatics analysis, variant interpretation and clinical reporting, post-test counseling and family risk discussion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |